MedTrace Logo

NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial

NCT01303640 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3235

Last updated 2015-12-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether the newly-approved biolimus-eluting stent is not inferior to the everolimus-eluting stent in terms of the rate of target-lesion revascularization at 1-year and death or myocardial infarction at 3-year after stent implantation in the real world clinical practice.

Conditions

Interventions

DEVICE

Biolimus-eluting stent

Biolimus-eluting stent

DEVICE

Everolimus-eluting stent

Everolimus-eluting stent

Sponsors & Collaborators

  • Takeshi Morimoto

    lead OTHER

Principal Investigators

  • Takeshi Kimura, MD, PhD · Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01303640 on ClinicalTrials.gov